FDA Announces OGD Leadership Positions As Part Of Reorganization

FDA Monday (July 21) unveiled key leadership positions as part of its reorganization of the Office of Generic Drugs, according to a memo from drug center Director Janet Woodcock. OGD was elevated to a super office to accommodate the passage of Generic Drug User Fee Amendments of 2012 (GDUFA) and a heightened focus on generic drugs. Most of the new assignments are in an acting capacity and are in preparation for the third year of GDUFA when goal dates go...